Unicycive, which is seeking an FDA green light for oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis, Monday said the agency set a target ...

Unicycive Therapeutics said the Food and Drug Administration accepted its application seeking approval of its lead drug candidate ... a condition involving too much phosphate in the blood that ...